Sentences with phrase «of cells from patients»

Paul Insel, MD, professor of pharmacology and medicine, will investigate the expression of the GPCR family of receptors on the surface of cells from patients with chronic lymphocytic leukemia (CLL).

This Korean researcher racked up a series of important advances in embryonic stem cell technology, including the first lines of cells from patients

Not exact matches

Speaking of Novartis — the company's experimental CTL019, which is expected to be the first approved drug in a revolutionary new cancer treatment space that turns the body's own immune cells into cancer - killers, is already facing some apprehension from doctors and patient groups who are worried about its eventual pricing.

«But at some point we'll be able fabricate a biodevice from a patient's own cells that will duplicate the most important functions of a kidney and that won't be rejected by the patient's immune system.»

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

This new kind of approach to fighting blood cancers is truly personalized; immune T - cells are extracted from patients, genetically tinkered to home in on an destroy cancerous cells, multiplied in a lab, and then jolted back into the patient's body within about two weeks.

«We look forward to leveraging all of our learnings and new capabilities from the initial launch of Kymriah in pediatric and young adult B - cell ALL for this larger group of patients.»

According to Science Daily, Dr. Nagy, senior investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, there is a «new method of generating stem cells that does not require embryos as starting points and could be used to generate cells from many adult tissues such as a patient's own skin cells.»

In November the Lancet published the results of an international research project whereby a Colombian lady received a new trachea (windpipe) which had been grown from a donor trachea (as it were, a «scaffold») repopulated with stem cells, for the very first time, from the patient's own body.

First, an adult cell would be removed from a patient and the DNA of that cell altered to control and direct the types of gene expression the nucleus is capable of supporting.

As we read this history, the furor over stem cells was fueled by numerous factors: the near - universal human desire for magic; patients» desperation in the face of illness and their hope for cures; the belief that biology can now do anything; the reluctance of scientists to accept any limits (particularly moral limits) on their research; the impact of big money from biotech stocks, patents, and federal funding; the willingness of America's elite class to use every means possible to discredit religion in general; and the need to protect the unlimited abortion license by accepting no protections of unborn human life.

In 1999, Anthony Atala grew a colony of bladder cells, taken from a biopsy and seeded on a «scaffold» in the shape of a patient's own bladder.

The study, published Feb. 5 in Nature Neuroscience, showed that the patients» nerve cells — converted directly from patients» skin cells — exhibited «symptoms» of the disorder, including DNA damage, dysfunctional mitochondria and cell death.

«In theory, we could model progression of the disease by reprogramming skin cells from patients at a range of ages, including before symptoms begin.

In a group of patients who underwent surgery for epilepsy, over half had stem cells where healthy individuals do not have them, according to a study from Sahlgrenska Academy.

The Muotri lab uses induced pluripotent stem cells from patients with autism and schizophrenia to look for biomarkers of these conditions.

STOP SIGNS Brainlike structures grown from autistic patients» stem cells (right) produced greater numbers of brain cells that make other brain cells less active (green and red) compared with structures grown from the cells of a non-autistic family member (left).

To develop their «disease in a dish» model, the team took skin cells from patients with Allan - Herndon - Dudley syndrome and reprogrammed them into induced pluripotent stem cells, which then can be developed into any type of tissue in the body.

At an early stage of development, the miniature organs grown from autistic patients» stem cells also showed faster cell division rates than those grown from the cells of non-autistic relatives.

In the March 22 online issue of Cancer Research, scientists explained how they injected triple negative breast cancer stem cells from patients into mice.

In blood samples from these patients, the researchers found an increase in the percentage of gamma delta T cells, similar to what they observed in mice, which remained stable over years.

For example, a consortium of research groups called the London Project to Cure Blindness aims to test RPE transplants from embryonic stem cells in patients with macular degeneration this year.

In collaboration with Anna Pyle, Howard Hughes Medical Institute investigator and professor in the Department of Molecular, Cellular and Developmental Biology at Yale, Patrizio and his team studied samples from 20 cumulus cells in 15 patients younger than age 35 and in those age 40 and older.

The decision was seen as an effort to mollify the religious fundamentalists at the core of Bush's political support who are ideologically opposed to deriving the cells from frozen embryos in fertility clinics and scientists and patients who hope that the cells could be used to help patients with Parkinson's, Alzheimer's, spinal - cord injuries, and diabetes.

Now, doctors at the University of Kiel in Germany have neatly bypassed the initial bone removal procedure and instead grown the required bone from stem cells in the patient's own bone marrow.

They stripped the knee joints of calves of all their cells with detergents and enzymes and then, based on digitized x-ray images from an anonymous patient, had machines carve them into cubic - centimeter - size human jaw joints.

They isolated blood cells from HIV - positive patients on antiretroviral therapy and at different stages of disease progression, as well as cells from non-infected individuals.

In contrast, PD - L1 blockade increased the capacity of Treg cells to multiply (and hence their overall numbers), but only in cells from patients with viremia, i.e. those that had detectable virus in their blood.

Creating a whole set of miniature new livers might take as little as obtaining liver cells from healthy donors and placing them inside the lymph nodes of patients suffering from liver disease.

So far, researchers with the Allen Institute for Brain Science in Seattle have described the intricate shapes and electrical properties of about 100 nerve cells, or neurons, taken from the brains of 36 patients as they underwent surgery for conditions such as brain tumors or epilepsy.

In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvania.

The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD.

Based on these ex vivo experiments (in cells isolated from patients and then exposed to PD - L1 blocking agents outside of the body), they predict that when actual patients are given PD - L1 blocking agents, their viral load at the time will influence the «net» outcome, i.e., whether the blockage boosts or weakens the overall anti-HIV immune response.

The Porteus team started with human stem cells from the blood of patients with sickle cell disease, corrected the gene mutation using CRISPR and then concentrated the human stem cells so that 90 percent carried the corrected sickle cell gene.

If the procedure works in humans, it would enable donated livers from humans, and possibly even from pigs, to be re-coated with a patient's own cells, reducing the likelihood of organ rejection.

However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells.

The Boston patients, in contrast, are free of the virus thanks to a combination of a bone marrow transplant plus continuing antiretroviral drugs to stop newly donated immune cells from being infected.

Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

Researchers analyzed peripheral blood mononuclear cells from a total of 18 children and adolescents in three matched groups: bipolar patients, unaffected offspring of bipolar parents and children of parents with no history of psychiatric disorders.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumor samples and discovered that specialized immune cells in brain tumor patients are compromised.

The results of the empirical study show a clear distinction between the damage to the white blood cells from patients with cancer, with pre-cancerous conditions and from healthy patients.

Lu's team will extract immune cells called T cells from the blood of the enrolled patients, and then use CRISPR — Cas9 technology — which pairs a molecular guide able to identify specific genetic sequences on a chromosome with an enzyme that can snip the chromosome at that spot — to knock out a gene in the cells.

Mice transplanted with cells grown from a patient suffering from Huntington's disease (HD) develop the clinical features and brain pathology of that patient, suggests a study published in the latest issue of Acta Neuropathologica by CHA University in Korea, in collaboration with researchers at Université Laval in Québec City, Canada.

One company, Melbourne, Australia — based Mesoblast, is already in late - stage clinical trials, treating hundreds of chronic heart failure patients with stem cell precursors drawn from healthy donors» hip bones.

The new findings build on prior research from the Dhodapkar lab demonstrating that patients with Gaucher disease, an inherited lipid storage disorder, have a significant increased risk for developing myeloma; and the discovery of a subset of lipid - reactive immune cells, called type II NKT - TFH, that promote the development of plasma cells.

Scientists from the University of Cambridge's Institute for Medical Research obtained skin cells from 10 patients — seven who had various forms of inherited liver disease, and three healthy controls.

Two men known only as the «Boston patients» have both stopped taking their anti-HIV medications following transplants of bone - marrow stem cells that appear to have banished the virus from their bodies.

Today's findings augment recent research also published in Nature (Dec. 7, 2016) detailing the team's development of a «stemness biomarker» — a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis which AML patients will respond to standard treatment.

These techniques include: human tissue created by reprogramming cells from people with the relevant disease (dubbed «patient in a dish»); «body on a chip» devices, where human tissue samples on a silicon chip are linked by a circulating blood substitute; many computer modelling approaches, such as virtual organs, virtual patients and virtual clinical trials; and microdosing studies, where tiny doses of drugs given to volunteers allow scientists to study their metabolism in humans, safely and with unsurpassed accuracy.

If researchers could reduce the loss of cells, they could one day treat two or even three times as many patients from the limited number of cadaver donors available, García noted.